Trial Profile
An Open Label, Phase 1 Study Evaluating Pharmacokinetics, Safety and Tolerability of ABT-869 in Subjects With Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Nov 2017
Price :
$35
*
At a glance
- Drugs Linifanib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Abbott Japan
- 01 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Apr 2012 Planned end date changed from 1 Dec 2012 to 1 Jun 2012 as reported by ClinicalTrials.gov.
- 23 Jan 2012 Planned end date changed from 1 Mar 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.